40% growth, 24% profit loss — the capex bill comes due

Kaynes hit 40% revenue growth—a genuine achievement—but net profit collapsed 24% to ₹56.4 Cr, slashing net margins to 5.9%. This is not a market miss or demand shock. It is capex in execution mode: the company is absorbing ₹1,200 crore in OSAT/PCB depreciation (with minimal revenue yet), cost inflation (components 30–35%, PCB 3x), lost QIP investment income (~2.5% of PAT), and the drag from metering receivables (₹1,311 Cr, collections only ₹88 Cr on ₹240 Cr sales). Management's tone is candid: 'a difficult year,' with normalization promised in 2–3 quarters. The market disagreed—stock down 5% by day 5, with FII and DII both trimming.

Start with ₹147.6 Cr EBITDA (15.6% OPM), flat to prior. Then subtract: (a) Depreciation surge from ₹700 Cr OSAT + ₹500 Cr PCB capex, (b) Lost QIP investment income ~₹12–15 Cr (no longer available—one-time cliff), (c) Component inflation pass-through lag—PCB cost up 3x, semiconductors 30–35%, pricing hasn't caught up Q-o-Q, (d) Metering receivables drag—business deliberately degrown to preserve cash, but collections only 37% of sales, (e) Forex headwind ~3.3% EBITDA impact. The cascade lands PAT at ₹56.4 Cr. What management controls: OSAT/PCB timeline and customer ramp (on track for Q3/Q4 FY27 revenue, but unproven). What it doesn't: component pricing and government payment timelines for metering.

Cash positive target delayed one year. FY26 guidance: 'cash positive by year-end.' Now: 'by end of FY27 year-end.' Q1 OCF -₹259 Cr, still deeply negative. Metering strategy unresolved. Two-year problem now in its third year; no decision announced. Revenue guidance reframed. Prior calls: '30–35% growth.' Now: '2x market growth' (same math, different framing, avoids absolute commitment). Margin recovery vague. NPM fell to 5.9% (-24.4% YoY); promised 'couple of quarters' normalization but zero targets attached. OSAT/PCB timing held. Q3/Q4 FY27 commercialization reaffirmed; validation progressing; Mitsui partnership (Japan access) + global EV customer contract imminent.

Price action speaks disappointment. Stock closed at ₹3,660 on day 7 (result announced day 1 at ₹3,856.30). Day-1 drop -3.14%, day-5 drop -5.09%—the market voted the quarter soft despite headline growth. The stock is now -47.7% off its all-time high, trading below its 200-day average (₹4,029.96), above the 50-day (₹3,371.15), RSI 69 (neutral). Volume normal. Institutional flows confirm skepticism. FII trimmed -1.46 percentage points to 5.82% (from 7.28% last quarter), DII -3.36pp to 11.78% (from 15.14%). Both are exiting. Promoters hold steady at 53.46%. The tape does not lie: growth at this price (and amid this execution risk) is not attractive enough to hold.

Kaynes is executing on a long-term strategy: build OSAT/PCB capacity (₹1,200 Cr capex), expand into space/aerospace/defense, grow EMS domestically (+53%, +2.4x market). The architecture is sound, and the order book (₹9,000 Cr) backs it. But this quarter showed execution risk, not opportunity. Profit collapsed despite growth (a mark of distress, not strength), metering receivables remain unresolved two years in, and management deflected on both the margin recovery path and the metering exit. Guidance was maintained but reframed (avoiding absolute targets) and key timelines were pushed (cash positive FY26 → FY27). The market's reaction—down 5% by day 5, FII/DII both exiting—reflects a fair judgement: the growth premium has been shed, and the company must now prove execution, not just articulate it.

This is a Steady quarter, not a step-change. The single number to track from here is net cash flow in H2 FY27—if metering collections and inventory absorption accelerate, the year-end cash positive target holds and confidence restores. If not, another year-end push signals structural stress, not temporary depreciation headwind. Until then, the bear case (capex ROI unproven, receivables unresolved, margin pressure persistent) outweighs the bull case (strategic initiatives, order book, topline growth).